Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects. Gene therapy could provide sustained anti-VEGF levels after a si...
Main Authors: | Kaiqin She, Jing Su, Qingnan Wang, Yi Liu, Xiaomei Zhong, Xiu Jin, Qinyu Zhao, Jianlu Xiao, Ruiting Li, Hongxin Deng, Fang Lu, Yang Yang, Yuquan Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050122000031 |
Similar Items
-
Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01) -
Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01) -
The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
by: Henrik Faatz, et al.
Published: (2022-11-01) -
Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization
by: Rui Gao, et al.
Published: (2021-01-01) -
Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration
by: Mehmet Ozveren
Published: (2020-08-01)